SCHEMBL348568

SCHEMBL348568

COc1cc(N)c(C(N)=O)cc1OC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.69
ALDH1A1 P00352 3/20 0.53
GAA P10253 2/20 0.53
GLA P06280 1/20 0.53
HPGD P15428 1/20 0.53
HTT P42858 2/20 0.47
CYP3A4 P08684 2/20 0.47
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
POLB P06746 1/20 0.44
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
HMGCR P04035 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24792666 0.88 MAPK1 (0.56) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL31715975 0.87 KDM4E (0.54) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL3549850 0.86 KDM4E (0.53) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL6814511 0.86 KDM4E (0.56) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL873953 0.85 KDM4E (0.53) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2605631 0.85 KDM4E (0.71) KDM4EALDH1A1GAAHTTCYP3A4
SCHEMBL31717018 0.85 KDM4E (0.51) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL28435087 0.85 KDM4E (0.51) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL5951822 0.85 GAA (0.58) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL17653164 0.85 KDM4E (0.51) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120079371-A Oxygen vacancy-containing tungsten trioxide catalyst and preparation method and application thereof 南京理工大学 2025-06-03 CN claimed
JP-11228515-A None JP disclosed
JP-59073558-A None JP disclosed
WO-2025227032-A1 METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-10-30 WO disclosed
CN-120079371-A Oxygen vacancy-containing tungsten trioxide catalyst and preparation method and application thereof 南京理工大学 2025-06-03 CN disclosed
CN-115260164-B Preparation method, structural composition and application of novel 4 (3H) -quinazolinone analogue in antitumor drugs 杭州星鳌生物科技有限公司 2024-03-26 CN disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ABBVIE INC (US) 2023-06-15 US disclosed
WO-2022262691-A1 HETEROCYCLIC COMPOUNDS AS SOS1 INHIBITORS BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2022-12-22 WO disclosed
WO-2022233253-A1 METHOD FOR PREPARING NEW 4(3H)-QUINAZOLINONE ANALOG, STRUCTURAL COMPOSITION THEREOF, AND USE THEREOF IN ANTITUMOR DRUGS 杭州星鳌生物科技有限公司 2022-11-10 WO disclosed
WO-1995027729-A1 OPIATE RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-10-19 WO disclosed
US-5371220-A Bicyclo-heterocyclic intermediates for cephalosporin compounds IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-12-06 US disclosed
US-5232918-A Bactericides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-08-03 US disclosed
EP-0251143-B1 2-Oxo-1-[[(Substituted Sulfonyl)Amino]-Carbonyl]Azetidines Bristol-Myers Squibb GmbH (DE) 1992-08-26 EP disclosed
US-5084457-A Cognition activators and nervous system disorders AMERICAN CYANAMID COMPANY (US) 1992-01-28 US disclosed
US-5019570-A Antibioics IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-05-28 US disclosed
US-5001157-A Substituted N-[[2-(aminocarbonyl)phenylamino]thioxomethyl]benzamides AMERICAN CYANAMID COMPANY (US) 1991-03-19 US disclosed
US-4801705-A 2-oxo-1-(((substituted sulfonyl)amino)-carbonyl)azetidines E. R. SQUIBB & SONS, INC. (US) 1989-01-31 US disclosed
EP-0251143-A1 2-Oxo-1-[[(Substituted Sulfonyl)Amino]-Carbonyl]Azetidines Bristol-Myers Squibb GmbH (DE) 1988-01-07 EP disclosed
JP-S5973558-A UREIDO DERIVATIVE AND ITS PREPARATION SANKYO CO LTD 1984-04-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183239-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, STING1 KDM4E 2697/4885ALDH1A1 1769/4885GAA 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.